)
)
)
The High-Impact Investment Landscape in Immunology & Inflammation
Expansion in the target landscape, from TL1A and beyond, has accelerated progress in I&I drug development with multibillion-dollar M&A across the past two years attracting more funding for programs in this space. This panel will explore the landscape of targets and indications showing the most promise to address unmet patient needs at large scale.